Millie
your market intelligence analyst
Search Results
820 results
Your search is now limited to «Gilead» expert search.
Contract Pharma 05/29/2020 10:08
Gilead will gain access to Arcus’s current and future investigational immuno-oncology products through the agreement, as Gilead continues to expand its presence in the field.
More from Contract Pharma:
PMLiVE 05/29/2020 08:20
Roche and Gilead Sciences are joining forcers to fight COVID-19 with a 450-patient trial that will combine two drugs already being tested against coronavirus as monotherapies.
More from PMLiVE:
Channel NewsAsia (Singapore) 05/28/2020 16:24
Gilead announced "top-line" findings from the trial on Apr 29.
More from Channel NewsAsia (Singapore):
Reuters.com 05/28/2020 13:06
Gilead study shows shorter 5-day course of remdesivir works as well as 10-day one.
More from Reuters.com:
Seeking Alpha 05/28/2020 12:03
Gilead Sciences Revenue - Gilead Sciences Investor Presentation Gilead Sciences core HIV and HCV sales continue to perform respectably.
More from Seeking Alpha:
Gilead Sciences chairman and CEO Daniel O’Day said: “Gilead is committed to accessing the world’s best innovation in immuno-oncology and our agreement with Arcus further demonstrates that commitment.
More from Pharmaceutical Business Review:
Xconomy 05/27/2020 18:31
Delaney worked at Gilead (NASDAQ: GILD) for more than 20 years, most recently as executive director of biology.
More from Xconomy:
Economic Times (India) 05/27/2020 17:38
Gilead has approached the government and questioned the application, said these persons.
More from Economic Times (India):
Zero Hedge 05/27/2020 17:25
Despite The Hype, Gilead's Remdesivir Will Do Nothing To End The COVID-19 Pandemic. Wed, 05/27/2020 - 17:25. Gilead Sciences' Remdesivir has been heralded as our in fighting the coronavirus pandemic. Unfortunately, the antiviral drug doesn’t seem of much help to patients with Covid-19, the disease caused by the coronavirus. And while the company’s clever rollout has generated excitement among investors, politicians, and the public, a combination of generic drugs that appears to be more effective in fighting the coronavirus has flown under the radar. Desperation for the limited supply of remdesivir is so great that Virginia will hold a lottery to determine which of the almost 1,500 severely ill patients in the state will be able to get its sev.
More from Zero Hedge:
Financial Post (Canada) 05/27/2020 16:33
Gilead Sciences Inc, which has suggested that a shorter treatment duration could extend limited supplies of its drug remdesivir, on Wednesday published results of a study showing no significant difference in outcomes between 5- and 10-day courses of the drug for patients with severe COVID-19.
More from Financial Post (Canada):
Zacks.com 05/27/2020 11:39
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology.
More from Zacks.com:
MarketWatch 05/27/2020 07:33
Last month people familiar with the matter told Bloomberg News that Gilead was considering a stake in Arcus.
More from MarketWatch:
Reuters.com 05/27/2020 07:17
Gilead Sciences Inc:
More from Reuters.com:
Business Wire 05/27/2020 07:11
We are very pleased to build on Gilead’s growing presence in immuno-oncology with this important new strategic collaboration with Arcus,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.
More from Business Wire:
Drudge Report 05/26/2020 23:49
Gilead has acknowledged the large role of government agencies in remdesivir's development but said that the original compound was discovered by Gilead researchers years earlier and that the government has no potential patent rights to the drug ...
More from Drudge Report:
The drug that buoyed expectations for a coronavirus treatment and drew international attention for Gilead Sciences, remdesivir, started as a reject, an also-ran in the search for antiviral drugs.
More from Seattle Times (United States):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications